Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.13, SHPH has negative trailing earnings (P/E not meaningful) and an ROE of -408.33%. Market capitalisation stands at $2M.
Balance sheet quality for SHPH: current ratio of 0.1, net cash position of $101858. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $3.13 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.47 |
| EV / EBITDA | -0.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -408.33% |
| Return on Invested Capital | -312.04% |
| Return on Assets | -91.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 0.30 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -10.78 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2M | 0.47 | -408.3% | |
| TAK | Takeda Pharmaceutical Company Limited | $59.3B | 50.64 | 1.20 | 2.4% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.9B | 58.46 | 5.53 | 9.2% |
| HLN | Haleon plc | $40.6B | 18.74 | 1.85 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.9B | 20.08 | 2.08 | 10.1% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price Performance
| 1 month | -20.15% |
| 3 months | -9.54% |
| Year-to-date | -82.61% |
| 1 year | -92.82% |
| 3 years | -99.76% |
52-Week Range
| 52-week High | $55.90 |
| 52-week Low | $2.58 |
| Avg Volume (90d) | 1.5M |
Related companies: AKAN · BBLG · BIVI · HSCS · IMCC · ISPC · MSPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SHPH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks